Stallergenes Greer

Name

Stallergenes Greer

Legal name

Stallergenes Greer International AG

Website

https://stallergenesgreer.com

Company type

Private

Founded year

1906

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

akta.pro secondary industry

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)

Keywords

• Allergen immunotherapy
• Biopharmaceutical products
• Allergy treatment
• Sublingual immunotherapy
• Venom immunotherapy

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Allergen Immunotherapy Products: Global biopharmaceutical company specializing in allergy through development and commercialization of allergen immunotherapy (AIT) products for diagnosis and treatment. Products include sublingual tablets (Actair, Staloral), sublingual liquid drops, subcutaneous immunotherapy (SCIT), and venom immunotherapy (Albey). Revenue from product sales through pharmaceutical distribution channels.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Stallergenes Greer is a global biopharmaceutical company that develops, manufactures, and commercializes allergen immunotherapy (AIT) products for the diagnosis and treatment of respiratory allergies (pollen, house dust mites, animal dander), food allergies (peanut), and Hymenoptera venom allergies. Its portfolio spans sublingual drops (Staloral), sublingual tablets (Actair), subcutaneous injections (SCIT), oral immunotherapy (Palforzia), and venom immunotherapy extracts (Albey), with a connected adherence device (iPUMP).

Product overview

Stallergenes Greer is a global biopharmaceutical company offering a comprehensive allergen immunotherapy portfolio with products available in multiple formulations: subcutaneous injections (SCIT), sublingual drops (Staloral®), sublingual tablets (Actair®), and oral immunotherapy (Palforzia®). The company also offers venom immunotherapy products (Albey® Venoms) and a connected health device (iPUMP®) developed with Aptar Digital Health to support treatment adherence. The portfolio covers respiratory allergies (pollen, house dust mites, animal dander), food allergies (peanut), and Hymenoptera venom allergies.

Differentiator

Problem solved

Functional benefit

Brands

• Actair: Sublingual immunotherapy (SLIT) tablet for house dust mite induced allergic rhinitis, commercialized in 21 countries.
• Staloral
• Palforzia
• Albey
• Actair/Orylmyte/Aitmyte
• iPUMP

Products and services

• Staloral Sublingual solution of allergen extracts for allergen immunotherapy (AIT) covering a broad spectrum of allergens including pollen, house dust mites, and animal dander. Available in multiple formulations for personalized treatment. Commercialized in 21 countries.
• Actair Sublingual allergen immunotherapy (SLIT) tablet for the treatment of house dust mite (HDM) induced allergic rhinitis. Commercialized in 21 countries and territories under brand names including Actair, Orylmyte, or Aitmyte.
• Palforzia Oral immunotherapy (OIT) treatment for peanut allergy, consisting of defatted powder of Arachis hypogaea L., semen (peanut). Designed to gradually increase tolerance through controlled desensitization. Approved for ages 1-17 (FDA) and 4-17 (EMA), with January 2025 EU approval expanded to toddlers ages 1-3.
• Albey Venoms Standardized purified extracts derived from Hymenoptera species including honeybee (Apis mellifera), yellow jacket (Vespula spp.), and paper wasp (Polistes spp.) for Venom Immunotherapy (VIT). Holds marketing authorizations in France, Italy, Australia and New Zealand.
• SCIT (Subcutaneous Immunotherapy) Allergen immunotherapy administered via subcutaneous injections under the skin of the arm (allergy shots). Given at a doctor's office with scheduled weekly or monthly dosing.
• SLIT (Sublingual Immunotherapy) Drops Flexible sublingual drops formulations allowing customization of frequency and allergen doses to meet individual patient needs. Enables treatment of uncommon allergens and dose adjustment during updosing and maintenance phases.

Quantifiable outcome

• 36% reduction in risk of new asthma events with SLIT-liquid treatment (EfficAPSI study, 440,000+ patients)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core, major and minor.

• Entomon s.r.l.coreStrategic or Co-development Partner · 7 January 2026Acquisition agreement signed January 2026, expected to close by end of January. Italian company specializing in production of certified stinging-insect venom extracts (Hymenoptera order) for diagnostic preparations and Venom Immunotherapy (VIT). Only company in Europe capable of extracting pure venom from Hymenoptera insects using proprietary Entomon Capillary Extracted Venom technology. Strengthens control of critical allergen extracts and secures long-term access to high-quality venom supplies.
• Nuance PharmamajorChannel Partner/ Reseller/ Distributor · 3 September 2025Exclusive long-term partnership for development and commercialization of Actair (house dust mite SLIT tablet) in China. Stallergenes Greer retains responsibility for development and registration while Nuance Pharma handles commercialization. Nearly 18% of China's population suffers from HDM-induced allergic rhinitis. Partnership aims to address significant treatment gap in Chinese market with AIT market projected to reach €1 billion within 10 years.
• CEOLIAcoreChannel Partner/ Reseller/ Distributor · 3 July 2025Appointed as new promotional partner for Actair in Japan starting July 3, 2025. Founded in 2010, CEOLIA is a pharmaceutical company dedicated to otolaryngology (ENT) field. Ensures continuity of patient care and healthcare professional support following transition from previous partner Shionogi.
• Shionogi & Co., Ltd.minorChannel Partner/ Reseller/ Distributor · 3 July 2025Previous promotional partner for Actair in Japan (license agreement established 2010). License ended July 2025 with transition to CEOLIA. Shionogi continues as Marketing Authorization Holder (MAH) during transition period and provides operational assistance to CEOLIA.
• Aptar Digital HealthcoreTechnology or Integration · 14 April 2025Joint development of iPUMP connected assistant for sublingual liquid AIT treatment. Aptar Digital Health, part of AptarGroup (global leader in drug and consumer product dosing), contributed connected pressure sensor technology and companion mobile application development. iPUMP is first connected assistant in allergology, launched February 2023, used by over 9,000 patients.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• DBV Technologies: French clinical-stage biotech developing Viaskin epicutaneous immunotherapy, including for peanut allergy. Competes with Stallergenes Greer in food allergy space but is earlier stage and uses a different delivery mechanism.
• Biomay AG: Austrian recombinant allergen immunotherapy developer, advancing next-generation recombinant AIT candidates. Comparable allergen immunotherapy focus but with a different technology platform (recombinant vs native extracts).
• Aimmune Therapeutics (Nestlé Health Science): Originally developer of Palforzia, acquired by Nestlé in 2020; Stallergenes Greer later acquired Palforzia rights from Nestlé in September 2023. Strong historical overlap, though Nestle/Aimmune no longer commercializes the peanut OIT asset.
• Aravax Pty Ltd: Australian clinical-stage company developing PVX108 peptide-based immunotherapy for peanut allergy. Adjacent competitor in food allergy, currently early-stage with a different molecular approach versus Palforzia's OIT.

Direct peers

• ALK-Abelló A/S: ALK-Abelló is the global leader in allergy immunotherapy, offering SCIT, SLIT tablets (e.g., Itulazax/Acarizax/Grass/Mite SLIT-tablets), and diagnostics. It is the most direct competitor across respiratory AIT in both developed and emerging markets.
• Leti Pharma: Spanish specialty allergen manufacturer producing AIT products for diagnosis and treatment of respiratory and venom allergies. Comparable focus on personalized allergen preparations and European market positioning.
• HAL Allergy Group: Dutch-headquartered specialty biopharmaceutical company focused on allergy diagnostics and immunotherapy (SCIT and SLIT). Comparable product breadth in allergen extracts and AIT formulations serving European and selected international markets.
• Roxall Group: German AIT manufacturer with subcutaneous and sublingual allergen products. Comparable European-centric focus, mid-sized presence, and allergen extract portfolio.
• Allergy Therapeutics plc: UK-based specialty vaccine and AIT company developing subcutaneous and sublingual allergen immunotherapy products (e.g., Pollinex Quattro, Oraltek). Directly comparable in AIT formulations, target indications, and geographic markets in Europe.

Broad incumbents

• Sanofi (Dupixent): Sanofi's Dupixent (dupilumab) is an approved biologic for allergic asthma, CRSwNP, and atopic dermatitis, often competing with AIT indications. Indirectly competes for the same patient prescriptions though via a different mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/stallergenesgreer
• Xx.com/stallergenescom
• Facebookfacebook.com/918128998272864

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stallergenes Greer